Equity Field Notes from temporal sources

[DanWebzster]

XERS is a biotech focusing on injectable products scheduled to IPO 6/18

Lead asset is a glucagon rescue pen

An NDA for the glucagon rescue pen is expected to be submitted Q3/18

The global TAM for this product is expected to reach $41B by 2022. There will be much competition.

XERS has 2 product platforms aimed at eliminating the need for reconstitution or refrigeration:

1) Xerisol for peptides and small molecules
2) Xeriject for biologics and large molecules (to reduce injection
volume)

The run-up into the FDA approval could be a very good trading opty.